Results 51 to 60 of about 9,892,286 (249)

Estimating the asbestos-related lung cancer burden from mesothelioma mortality. [PDF]

, 2012
BACKGROUND: Quantifying the asbestos-related lung cancer burden is difficult in the presence of this disease's multiple causes. We explore two methods to estimate this burden using mesothelioma deaths as a proxy for asbestos exposure.
Byrnes, G, Byrnes, G., G Byrnes, P Boffetta, Peto, J, J Peto, McCormack, V, Straif, K, Boffetta, P, V McCormack, McCormack, V., Straif, K., K Straif, Peto, J., Boffetta, P.   +14 more
core   +1 more source

Metastatic niche shaped by host factors influences disseminated cancer cell fate

FEBS Letters, EarlyView.
Metastasis is shaped not only by cancer cells but also by the environments they encounter. This review explores how factors such as aging, diet, the microbiome, lifestyle, and environmental exposures remodel organ‐specific niches in the lung, liver, bone, and brain, influencing where metastatic cells survive, remain dormant, or grow, and ultimately ...
Gwennan Delyth Ward, Álvaro Ruiz‐Tabas, Patricia Altea‐Manzano   +2 more
wiley   +1 more source

Intertumoural Heterogeneity and Branch Evolution of Synchronous Multiple Primary Lung Adenocarcinomas by Next-Generation Sequencing Analysis

Frontiers in Oncology, 2021
ObjectivesMultiple primary lung cancers (MPLCs) are an increasingly well-known clinical phenomenon, but there is a lack of high-level evidence for their optimal clinical diagnosis and therapeutic approaches.
Qinleng Zhang, Qinleng Zhang, Hui Jia, Zhendan Wang, Shaoyu Hao, Haiyan Huang, Airong Yang, Lu Han, Pingping Song   +8 more
doaj   +1 more source

Hijacking emergency granulopoiesis: Neutrophil ontogeny and reprogramming in cancer

Molecular Oncology, EarlyView.
Neutrophils are highly plastic innate immune cells; their functions in cancer extend beyond the tumour microenvironment. This Review summarises current understanding of neutrophil maturation and heterogeneity and highlights tumour‐induced granulopoiesis as a systemic programme that expands immature, immunosuppressive neutrophils via tumour‐derived ...
Gabriela Marinescu, Yi Feng
wiley   +1 more source

Surgical Treatment of Synchronous Multiple Primary Lung Cancer: Report of Two Cases

Southern Clinics of Istanbul Eurasia, 2017
The presence of more than 1 distinct lung cancer in the same patient, or multiple primary lung cancer (MPLC) is a rarely seen condition. Multiple lung cancers are classified as synchronous when more than 1 type of lung cancer is detected at the same time,
Recep Demirhan, Kadir Burak Özer, Ekin Ezgi Cesur, Attila Özdemir, Dilek Ece, Fatma Tuğba Özlü   +5 more
doaj   +1 more source

Metachronous primary lung adenocarcinomas harboring distinct KRAS mutations

Thoracic Cancer, 2020
To distinguish whether multiple lung nodules represent multiple primary lung cancers (MPLC) or intrapulmonary metastases (IPM) is crucial for staging and subsequent therapy. We herein present the first report of a patient with two simultaneously resected
Yan Hu, Siying Ren, Chen Chen, Qingchun Liang, Fenglei Yu, Wenliang Liu   +5 more
doaj   +1 more source

Metastasis on pause: How dormant tumor cells stay hidden within the tumor microenvironment and evade immune surveillance

Molecular Oncology, EarlyView.
Dormant cancer cells can hide in distant organs for years, evading treatment and the immune system. This review highlights how signals from the surrounding tissue and immune environment keep these cells inactive or trigger their reawakening. Understanding these mechanisms may help develop therapies to eliminate or control dormant cells and prevent ...
Kanishka Tiwary, Jose Javier Bravo‐Cordero   +1 more
wiley   +1 more source

Second Primary Cancers After Liver, Gallbladder and Bile Duct Cancers, and These Cancers as Second Primary Cancers

, 2021
Guoqiao Zheng,1– 3 Kristina Sundquist,3– 5 Jan Sundquist,3– 5 Tianhui Chen,6 Asta Försti,1,4,7,8 Akseli Hemminki,9,10 Vaclav Liska,11,12 Kari Hemminki1,2,4,12 1Division of Molecular Genetic Epidemiology, German Cancer Research Center (DKFZ), Heidelberg ...
Sundquist J, Sundquist K, Forsti Asta, Försti A, Liska V, Zheng Guoqiao, Sundquist Kristina, Hemminki K, Sundquist Jan, Chen Tianhui, Hemminki Akseli, Liška Václav, Zheng G, Hemminki A, Hemminki Kari Jussi, Chen T   +15 more
core   +1 more source

Developmental programmes drive cellular plasticity, disease progression and therapy resistance in lung adenocarcinoma

Molecular Oncology, EarlyView.
This study shows that lung adenocarcinomas exploit developmental branching morphogenesis to acquire a therapy resistant basal‐like tumour cell state. This process was found to be regulated by combined TP53 loss‐of‐function and type‐I interferon signalling, identifying a novel axis for biomarker and therapeutic target discovery.
Kamila J Bienkowska, Stephany Gallardo, Nur S. Zainal, Leena Arora, Matthew Ellis, Maria‐Antoinette Lopez, Judith Austine, Sai Pittla, Serena J Chee, Aiman Alzetani, Emily C Shaw, Christian H Ottensmeier, Gareth J Thomas, Christopher J Hanley   +13 more
wiley   +1 more source

Stimulator of interferon genes agonist augmented antitumor immunity of osimertinib in Egfr‐mutated lung cancer

Molecular Oncology, EarlyView.
Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura, Tadahiro Kuribayashi, Johannes Brägelmann, Sachi Okawa, Masataka Taoka, Shunta Mori, Tomoka Nishimura, Takaaki Tanaka, Go Makimoto, Kiichiro Ninomiya, Kammei Rai, Eiki Ichihara, Ryohei Katayama, Katsuyuki Hotta, Masahiro Tabata, Yosuke Togashi, Yoshinobu Maeda, Martin L. Sos, Katsuyuki Kiura, Kadoaki Ohashi   +19 more
wiley   +1 more source